CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

Right arrow Help viewing high resolution images
Right arrow Return to article
Click on image to view larger version.



Fig. 5. Effects of bryostatin-1 + GM-CSF on primary AML samples. Isolated AML blasts were incubated for 120 h in the absence (Control) or presence of bryostatin-1 (10-8 M) with or without GM-CSF (200 units/ml) and assayed for CD15 expression (A) and clonogenic growth (B). Results represent the means for the seven patient specimens; bars, SE. P = 0.002 was determined by ANOVA for the comparison of all treatment groups for both CD15 expression (A) and clonogenic growth (B).





Right arrow Return to article


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation